Shots:
- The P-III (FRONTIER3) trial assessed Mim8 (SC) in 70 pts (1-11yrs.) with hemophilia A ± FVIII inhibitors in 2 parts: P1 involves Q1W prophylaxis therapy until 26wks. after which pts can stay on Q1W or switch to QM for further 26wks.; regulatory filings expected in 2025
- P1 data showed 0.53 mean & 0 median ABR, with 74.3% pts (incl.14 hemophilia A pts with inhibitors) having 0 treated bleeds. After 26wks., 45% switched to Mim8 (QM)
- Pts- & caregiver-reported data from P1 showed that Mim8 might reduce treatment burden with positive trends observed in physical function & QoL scores in 26wks. Data presented at EAHAD 2025; full data to be presented in future meetings & publications (2025-26)
Ref: Globenewswire | Image: Novo Nordisk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
